SCHEMBL4167341

SCHEMBL4167341

Cc1nc(-c2cccs2)sc1C=CC(=O)N(C)C

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.53
ALDH1A1 P00352 6/20 0.51
GAA P10253 3/20 0.49
RAB9A P51151 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
GLA P06280 1/20 0.41
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 2/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 2/20 0.37
HPGD P15428 2/20 0.37
NPC1 O15118 2/20 0.37
POLB P06746 2/20 0.37
KMT2A Q03164 4/20 0.36
NLRP1 Q9C000 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4164806 0.77 KDM4E (0.36) KDM4EALDH1A1GAARAB9ASMN1; SMN2
SCHEMBL6168006 0.77 KDM4E (0.57) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL4160113 0.76 MAPT (0.37) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL2412008 0.76 CYP1A2 (0.54) KDM4EALDH1A1RAB9ALMNASMN1; SMN2
SCHEMBL4154288 0.74 HSD17B10 (0.43) KDM4EALDH1A1GAARAB9ALMNA
SCHEMBL4161913 0.74 CCNC (0.36) KDM4EALDH1A1GAARAB9AGLA
SCHEMBL2076088 0.73 NR4A2 (0.35) KDM4EALDH1A1GAARAB9ALMNA
SCHEMBL4167344 0.72 ALDH1A1 (0.67) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL4167350 0.72 NR4A2 (0.32) HPGD
SCHEMBL2075029 0.72 JAK2 (0.42) KDM4EALDH1A1RAB9AL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 KDM4E 2234/4885ALDH1A1 2743/4885GAA 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.